Approximately one third of all colorectal malignancies are located in the rectum. It has long been recognized that rectal cancers behave differently from colonic tumors, namely in terms of local recurrence. For this reason, specific protocols have been developed to manage this disease both in staging procedures as well as in neoadjuvant and adjuvant chemoradiation treatments. Magnetic resonance imaging is now obligatory for rectal cancer staging. Also, preoperative chemoradiation is recommended in the large majority of locally advanced rectal cancers with obvious advantages in downstaging and downsizing tumors, sometimes allowing spincteric-sparing procedures. Total mesorectum excision is now the rule when operating on rectal cancer. Despite these advances, there are still unanswered questions, namely the utility of using neoadjuvant protocols in low lying, early stage tumors with the aim of performing a local excision procedure and the utility of re-staging the disease after neo-adjuvant treatment. In fact, response to neoadjuvant therapy may become a cornerstone of rectal cancer treatment and individualized therapy. Finally, there is the concern that with current protocols, we are overtreating some patients that would not need such extensive treatment.In this review, we critically examine recent advances in staging, surgery, and chemoradiation in the management of patients with rectal cancer which have not typically been incorporated in published treatment guidelines
1 April 2008 in Archives of Endocrinology and Metabolism
O carcinoma com diferenciação semelhante a timo (CASTLE) é uma neoplasia epitelial maligna rara, que surge nos tecidos moles do pescoço ou na glândula tireóide. O diagnóstico diferencial deve ser estabelecido com carcinoma pavimento-celular primário ou secundário da cabeça e do pescoço ou da tireóide, visto que têm prognósticos distintos. A imunorreatividade para CD5 pode ser útil no diagnóstico de CASTLE. O CASTLE possui elevada taxa de recidiva local, apesar de o seu curso clínico indolente, ao contrário das neoplasias previamente referidas, que têm um prognóstico muito reservado, dada a elevada taxa de disseminação sistêmica. O tratamento inclui excisão cirúrgica e radioterapia. A quimioterapia também tem sido realizada, apesar de até a presente data não existir evidência clara da sua eficácia. Relata-se caso de doente de sexo masculino, com 52 anos, que surge com tosse seca, disfonia e massa da tireóide, que foi submetido à tireoidectomia. O exame anatomopatológico da peça operatória permitiu o diagnóstico de CASTLE. O doente efetuou radioterapia e quimioterapia e obteve resposta mínima. Pretende-se discutir o diagnóstico anatomopatológico diferencial e a abordagem terapêutica mais adequada de uma patologia com prognóstico favorável, mas de natureza recidivante, que exige seguimento rigoroso a longo prazo.
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited prognostic biomarkers after curative-intent resection. We aim to determine if loss of SMAD4 protein expression has prognostic significance in operated PDAC patients. Methods: SMAD4 protein expression was evaluated by immunohistochemistry (IHC) in resected PDAC tu-mours from patients treated at two centers. The prognostic significance of SMAD4 expression status and clinical outcomes, namely overall survival (OS) and recurrence-free survival (RFS), was assessed using survival analysis with Kaplan–Meier estimation and Cox proportional hazards regression models. Results: A total of 87 patients with resected PDAC were included in the final analysis, with a median follow-up of 75.9 months. In univariable analysis, SMAD4 expression status was not associated with OS (intact vs. lost: HR = 0.87, p = 0.56) or RFS (HR = 0.84, p = 0.51). In multivariable analysis, SMAD4 expression was not an independent prognostic factor for OS (HR = 0.94, p = 0.81) or RFS (HR = 0.82, p = 0.49). Established clinicopathological variables, including histological grade, nodal status, postoperative CA19-9 levels, and adju-vant treatment, were independently associated with both survival outcomes, while resection status was inde-pendently associated with OS. Conclusions: In this bicentric cohort, loss of SMAD4 expression assessed by IHC was not an independent prognostic marker for OS or RFS of resected PDAC. Despite the potential SMAD4 relevance within specific biological or clinical subgroups, further studies are warranted to clarify the role of SMAD4 in PDAC risk strati-fication and support the development of integrated molecular and clinicopathological prognostic models.
2 January 2026 in Cancer Treatment and Research Communications
The prognostic value of SMAD4 in pancreatic cancer has been evaluated in several studies. However, the conclusions remain controversial. Therefore, we aimed to evaluate the prognostic value of the SMAD4 gene in pancreatic cancer to aid in the design of therapeutic strategies. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and the proposed methodology was registered on PROSPERO. An electronic search was made in MEDLINE (via PubMed), Web of Science and Google Scholar to identify all relevant studies. Eligible studies were those written in English including patients with Pancreatic Ductal Adenocarcinoma (PDAC), who underwent pancreatic surgery with curative intent and provided data on SMAD4 gene status or SMAD4 protein expression and its association to prognosis, measured by overall survival (OS). The effect measure of interest was the hazard ratio (HR) for OS between PDAC with or without SMDA4 mutations. A total of 24 studies on SMAD4, with 4340 samples, were included in this systematic review and meta-analysis. Our pooled results demonstrated that patients with tumours with SMAD4 alteration had significantly worse prognosis for OS (HR= 1.43, 95% CI = 1.17-1.76, p-value = 0.002). This systematic review and meta-analysis support the use of driver mutations in the SMAD4 gene as a prognostic marker for pancreatic cancer.
At the time of the first wave of the COVID-19 pandemic, patients with cancer were considered to be at high risk of serious illness and had a higher exposure risk since they needed frequent and nondeferrable hospital visits. Serological tests were not routinely used, and seroprevalence in this population was unknown. A single-center, cross-sectional study was developed to determine the seroprevalence of anti-SARS-CoV-2 antibodies (Abs) in patients with cancer undergoing systemic antineoplastic treatment. One hundred patients were consecutively recruited in a two-week period (6th-20th May 2020), and serum samples were tested for the presence of immunoglobulin M (IgM) and immunoglobulin G (IgG) Abs directed against both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins in two distinct time points (at recruitment and 4-8 weeks later). IgG-positive results were subject to confirmation, in the same serum sample, using two distinct assays. At the time of the first study visit, no patient had a previously confirmed diagnosis of COVID-19, one reported previous contact with a COVID-19 patient, and all had a baseline SARS-CoV-2-negative RT-PCR. Two patients tested positive for SARS-CoV-2 IgG in the first study visit, which was not confirmed in either of the two confirmatory assays. Seventy-two patients were tested at the second study visit, all with negative IgG tests. IgM was persistently positive at both study visits in one patient and was positive in another patient at the second study visit, both with negative RT-PCR and serum IgG. No patient tested positive for RT-PCR within the study timeframe. No evidence of prior or acute SARS-CoV-2 infection was documented in this cohort of patients with cancer undergoing systemic treatment, and no additional exposure risk was documented compared to general population seroprevalence studies. The study was inconclusive regarding the role of SARS-CoV-2 serology in patients with cancer in the early phase of the pandemic. This study did show that, with adherence to recommended preventive measures, it was safe to maintain systemic cancer therapy.